Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01814514|
Recruitment Status : Unknown
Verified March 2013 by Zahra Rabbani Khah, Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : March 20, 2013
Last Update Posted : March 20, 2013
The AGV implant is designed to open when the IOP is between 8 mmHg and 10 mmHg, and thus maintains an IOP of 8 mmHg or higher. In the early period after glaucoma drainage device (GDD) surgery the intraocular pressure (IOP) classically goes through 2 phases. The hypotensive phase occurs immediately after surgery, lasts around 1 week. This is followed by the hypertensive period where the IOP tends to rise steadily above 21mmhg.
The hypertensive response seems to occur more commonly after Ahmed GDD surgery than nonvalved implants, It was reported to occur in 40% to 80% of cases. Although the hypertensive phase can last as long as 6 months it is usually during the first 1 to 4 weeks, when there is intense congestion of the bleb wall, that IOP is highest.
Previous study showed that when aqueous comes into contact with conjunctiva and Tenon's capsule,an inflammatory reaction occurs.Factors such as prostaglandins, eicosanoids, tissue growth factor beta (TGF β)has been shown to occur in glaucomatous aqueous. These mediators induce an inflammatory reaction, and if excessive, will result in fibrosis and poor functioning of the bleb. High pressure within the bleb also results in the secretion of TGF β by the bleb lining. It may result in inflammation of the bleb wall and subsequent fibrosis and poor bleb function. The investigators supposed that with early use of aqueous suppressant medication after AGV implantation, the concentration of inflammatory mediators decreased in subconjunctival space and may lead to better IOP control after shunt surgery.
|Condition or disease||Intervention/treatment||Phase|
|Hypertensive Phase||Drug: Timolol-trusopt Drug: placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||94 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Early Intra Ocular- Pressure Control Using Aqueous Suppressive Agents After Ahmed Glaucoma Valve Implantation|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||March 2013|
Active Comparator: Timolol-trusopt
Dosage:One drop/12hours,duration:3 months
Other Name: cosopt
Placebo Comparator: placebo,Artificial tear
dosage:one drop/12 hours,duration:3 months
- intraocular pressure-hypertensive phase success rate [ Time Frame: during first 3 months ]during first 3 months
- intraocular pressure success rate [ Time Frame: after 12 months ]after 12 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01814514
|Contact: Mohammad pakravan, Associate Professoremail@example.com|
|Iran, Islamic Republic of|
|Labbafinejad medical center||Recruiting|
|Tehran, Iran, Islamic Republic of|
|Contact: Mohammad Pakravan, Associate Professor firstname.lastname@example.org|
|Principal Investigator: Mohammad Pakravan, Associate Professor|